Sei Investments Co. Purchases New Position in AngioDynamics, Inc. $ANGO

Key Points

• Sei Investments Co. has acquired a new position in AngioDynamics, purchasing 31,500 shares valued at approximately $295,000, marking their ownership at 0.08% of the company.
• AngioDynamics recently reported quarterly earnings, surpassing expectations with revenue of $80.16 million and earnings per share of ($0.03), indicating a 13.0% increase in revenue year-over-year.
• Several institutional investors have significantly increased their stakes in AngioDynamics, with notable changes including a 667.0% stake increase by the New York State Common Retirement Fund during the first quarter.

Sei Investments Co. purchased a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 31,500 shares of the medical instruments supplier's stock, valued at approximately $295,000. Sei Investments Co. owned approximately 0.08% of AngioDynamics as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ANGO. Nuveen LLC bought a new stake in shares of AngioDynamics during the first quarter valued at approximately $10,803,000. Bastion Asset Management Inc. bought a new stake in shares of AngioDynamics during the first quarter valued at approximately $6,601,000. Divisadero Street Capital Management LP bought a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $4,714,000. AIGH Capital Management LLC bought a new stake in AngioDynamics in the first quarter worth $4,455,000. Finally, Marshall Wace LLP boosted its holdings in AngioDynamics by 1,335.1% in the fourth quarter. Marshall Wace LLP now owns 476,824 shares of the medical instruments supplier's stock worth $4,368,000 after acquiring an additional 443,598 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on ANGO. Canaccord Genuity Group boosted their target price on AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, July 16th. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a research note on Wednesday, July 16th. Finally, Lake Street Capital assumed coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $19.00.

AngioDynamics Price Performance

Shares of NASDAQ ANGO traded up $0.2760 during mid-day trading on Wednesday, reaching $9.1060. The company's stock had a trading volume of 238,373 shares, compared to its average volume of 630,785. The firm has a market capitalization of $369.98 million, a PE ratio of -10.98 and a beta of 0.67. The stock has a fifty day moving average of $9.35 and a two-hundred day moving average of $9.62. AngioDynamics, Inc. has a 52 week low of $5.83 and a 52 week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. The firm had revenue of $80.16 million during the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. Analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.